Introduction
============

*Staphylococcus aureus* (*S. aureus*) is an important human pathogen that causes the acquired infectious diseases in the hospital and community ([@b17-bjm-44-267]; [@b28-bjm-44-267]). The increasing incidence of *S. aureus* infections through both the healthcare and community settings, are rapidly promoting *S. aureus* to acquire the antibiotic resistance to both first-line and more novel antibiotics. The number of antibiotic resistance isolates of *S. aureus* is rapidly increasing ([@b2-bjm-44-267]; [@b7-bjm-44-267]; [@b11-bjm-44-267]; [@b15-bjm-44-267]; [@b26-bjm-44-267]). Of which, the methicillin-resistant *S. aureus* (MRSA) is the most important and the morbidity and mortality of these infectious diseases caused by MRSA is very high. Relying solely on the antibiotic therapy for *S. aureus*-related disease becomes increasingly difficult. Therefore, to develop effective and safe vaccine of *S. aureus* has once again become one of the world's hot spots. Thus far there is no very ideal *S. aureus* vaccine for clinical application. To seek the ideal target genes is the key to develop effective and safe vaccine of *S. aureus*.

*S. aureus* pathogenesis in the host relies on the secretion of virulence factor through the secretion system ([@b1-bjm-44-267]; [@b12-bjm-44-267]; [@b25-bjm-44-267]). It was reported that the recently named type VII secretion system(T7SS) was present in *S. aureus* ([@b1-bjm-44-267]; [@b12-bjm-44-267]; [@b25-bjm-44-267]). The T7SS was first found in the *Mycobacterium tuberculosis*, and the T7SS could secret ESAT-6 (early secreted antigen target 6 kDa) which could trigger cell-mediated immune response in host ([@b21-bjm-44-267]; [@b27-bjm-44-267]). The T7SS of *S. aureus* has the ability to secret ESAT-6 like proteins EsxA and EsxB to the extracellular surroundings ([@b3-bjm-44-267]). The locus of gene *esxA* and *esxB* is arranged with other six genes in the Ess gene cluster. Some genes in this gene cluster such as *essA*, *essB*, and *essC* are necessary for the synthesis and secretion of EsxA and EsxB. It was reported that the secretion of EsxA and EsxB was prevented in the absent of *essA*, *essB*, and *essC* ([@b3-bjm-44-267]).

The abscess formation is the most important for the virules of *S. aureus* ([@b4-bjm-44-267]; [@b8-bjm-44-267]; [@b20-bjm-44-267]). There have been shown that *S. aureus* strains were reduced obviously capacity of the formation abscesses in the infection process of mice only when sortase mutants defective ([@b14-bjm-44-267]; [@b18-bjm-44-267]). However it was recently reported that the *esxA* mutant strain show the obvious defect in the formation of abscess in infected mice ([@b3-bjm-44-267]), and this suggests that EsxA may play an important role in the process of the pathogenesis for *S. aureus*. Therefor, EsxA was hopeful to become the candidate antigen for the development of *S. aureus* vaccine.

In this study, *S. aureus* was isolated from the clinical specimens of hospitalized patients who came from 10 different ward areas and the antimicrobial susceptibility assay was determined according to 2010 CLSI recommendations ([@b5-bjm-44-267]). At the same time, the sera of the patients with *S. aureus* infection were collected. And then the protein EsxA of *S. aureus* was prepared and used as the antigen to detect the anti-EsxA antibodies in the serum of the patients with *S. aureus* infection by the indirect ELISA.

Materials and Methods
=====================

Collection of strains and serum
-------------------------------

The Second Affiliated Hospital of Soochow University (1231 beds) is one of the largest hospital in Suzhou, China. Isolates of *S. aureus* were obtained from the clinical specimens of hospitalised patients from June 2010 to April 2011. Isolates were confirmed as *S. aureus* using a Staph SPA agglutination kit, Gram's stain and Phoenix System-100 BD Automated Microbiology analyser (BD Diagnostics, USA). At same time, 78 clinical sera were obtained from the coherent patients with *S. aureus* infection. The *S. aureus* isolates were mainly associated with lung infection and pyogenic soft-tissue infection and pyogenic post-operative wound surface infections in patients from 10 different ward areas such as the intensive care unit. Every *S. aureus* strain was isolated from different patients, one strain was corresponding to one patient. Fifty negative control sera were collected from the hospital medical center healthy people.

Antimicrobial susceptibility
----------------------------

Isolates of *S. aureus* were inoculated onto the Phoenix panel according to the manufacturer's instructions and then the identification and antimicrobial susceptibility of these isolates were determined by Phoenix System-100 BD Automated Microbiology (BD Diagnostics, USA). Results of Minimum Inhibitory Concentrations (MICs) were recorded according to 2010 CLSI criteria ([@b5-bjm-44-267]). Methicillin-resistant *Staphylococcus* aureus (MRSA) was confirmed if MIC of oxacillin \> 4 μg/mL. *S. aureus* ATCC 29213 were used as a quality control strain for antimicrobial susceptibility testing.

Preparation of the protein EsxA of *S. aureus*
----------------------------------------------

The *esxA* gene was amplified with the following primer pairs: 5′-GC[GGATCC]{.ul}ATGGCAATGATTAAGA TGAG-3′ and 5′-AA[CTCGAG]{.ul}TTGCAAACCGAAATT ATTAG-3′. The PCR products were cloned into the pGEM-T Easy vector to yield plasmids pGEM-*esxA*. The gene was cut out from the plasmid with the restriction endonucleases *Bam*H I and *Xho* I and cloned into the pET-28a vector to generate pET-28a-*esxA*, verified by sequencing *esxA* gene. Plasmid pET-28a-*esxA* was designed for the heterologous protein expression in *E. coli* Rosetta (Ros) to synthesize the N-terminal histidine-tagged recombinant proteins. *E. coli* Ros cells carrying pET-28a-*esxA* were grown in LB medium containing ampicillin (100 μg/mL) at 37 °C for 16 h. An aliquot (1 mL) of an overnight culture was used to inoculate 100 mL of the same medium and incubated at 37 °C with shaking (250 rpm) until the OD600 of culture reached 0.6. Expression of the recombinant proteins was induced for 3 h at 37 °C by the addition of IPTG to a final concentration of 100 μM. Cells were harvested by centrifugation at 6,000 *g* at 4 °C for 10 min, and resuspended in 10 mL of binding buffer (5 mM imidazole, 0.5 M NaCl, and 5 mM Tris-HCl; pH 7.9). The recombinant proteins EsxA~his6~ carring 6 His tag were purified from cell lysate fraction by affinity chromatography with Ni^2+^-NTA system (QIAGEN, Cologne, Germany) according to the manufacturer's protocol. After extensive washing, the bound proteins were eluted with 5 mM Tris-HCl buffer (pH 7.9) containing 0.2 M imidazole and 0.15 M NaCl. Purified proteins were identified by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 12% polyacrylamide gels and stained with Coomassie brilliant blue. Protein concentration was determined by a protein assay reagent (Bio-Rad, California, USA) and with bovine serum albumin as the standard.

Detection of the anti-EsxA antibody in serum by the indirect ELISA
------------------------------------------------------------------

The purified EsxA antigen was diluted to 20 ng/μL. The 96-well ELISA plates were coated with the above diluted EsxA antigen by 10 μLper well, and then put at 4 °C overnight. The ELISA plates were washed with washing Phosphate Buffered Saline Tween-20 (PBST) three times, each for min dried through pat, and then add 10 μL 10% fetal calf serum into each well. After incubated for 1 h at room temperature, the ELISA plates were washed as above, and then add 10 μL tested serum into each well. After incubated at 37 °C for 1 h by the water bath, the ELISA plates were washed as above too. Then, add 10 μL horseradish peroxidase labeled goat anti-human HRP-IgG into each well, and incubate the ELISA plates at 37 °C for 1 h by water bath. At last, wash the ELISA plates with buffer PBST five times, each for min then pat the plates for dry; add substrate buffer A, B the role of 5 μL into each well for 30 min, and then add 2 mol/L sulfuric acid 10 μL into each well to stop the reaction. Absorbance values (OD~450~) were measured by Microplate Reader Model 680 BIO-RAD Japan). Each experiment was performed three times. The anti-EsxA antibodies in 50 healthy human sera were tested by indirect ELISA assay and calculated the average OD~450~ value mean (M) and Standard deviation (SD). The value of M+2SD was defined as the threshold value. When the OD~450~ value of the tested serum was greater than M+2SD, the sample was classified as a positive sample.

Results and Discussion
======================

*S. aureus,* one of the most important pathogens mainly spread in the community and hospital*,* can cause superficial infections, osteomyelitis, pneumonia, septic arthritis, endocarditis, meningitis, and even can lead to sepsis or other systemic infection ([@b17-bjm-44-267]). In recent years, due to the overuse of antibiotics, a variety of new strains of antibiotic resistant have appeared, such as MRSA strain ([@b6-bjm-44-267]; [@b10-bjm-44-267]; [@b19-bjm-44-267]; [@b23-bjm-44-267]) and new-found vancomycin-insensitive *S. aureus* (Vancomysin-intermediate *S. ureus*, VISA) strain ([@b13-bjm-44-267]; [@b30-bjm-44-267]). Those drug-resistant strains make it more difficult to treat *S. aureus* infection. There was reported that *S. aureus* whole-cell vaccine ineffective in clinical, and thus development of effective of vaccine should to find other antigens which could stimulate protective antibodies ([@b16-bjm-44-267]; [@b29-bjm-44-267]), but some clinical study results about *S. aureus* vaccine developed based on some antigens such as capsular polysaccharide antigen were not satisfactory ([@b9-bjm-44-267]; [@b22-bjm-44-267]; [@b24-bjm-44-267]). So far, there was no ideal of *S. aureus* vaccine.

This study constructed EsxA prokaryotic expression system successfully. *E. coli* Ros cells harboring pET-28a-EsxA was grown in liquid medium at 37 °C for 3 h in the presence of 0.1 mmol/L IPTG. One predominant band corresponding to the molecular mass of approximately 16 kDa was observed in the crude extract of IPTG-induced *E. coli* ([Figure 1](#f1-bjm-44-267){ref-type="fig"}). The recombinant protein in the crude extract was purified by nickel-chelate column chromatography. The purified EsxA was apparently homogenous in the 16 kD protein bands as judged by SDS-PAGE ([Figure 1](#f1-bjm-44-267){ref-type="fig"}). As shown in [Figure 1](#f1-bjm-44-267){ref-type="fig"}, EsxA was purified to near homogeneity by Ni^2+^-NTA, consistent with the experimental design. In order to understand EsxA might be as a virulence factor inducing the production of anti-EsxA antibodies in patients with *Staphylococcus aureus* infection. We further used the purified EsxA protein antigen to detect the anti-EsxA antibodies in serum of patients with *S. aureus* infection by indirect ELISA. The antibody level of EsxA in 50 healthy serum samples was tested and the mean OD~450~ value (M) and standard deviation (SD) were 0.110 and 0.120, respectively. The value of M+2SD was defined as cutoff which was 0.350. It meant that the tested sample was anti-EsxA antibody positive when OD~450~ value was greater than 0.350. Among the tested 78 clinical samples, 19 samples were positive and the positive rate was 24.35%. The result was shown in [Table 1](#t1-bjm-44-267){ref-type="table"}.

These results indicated that EsxA might be as a virulence factor inducing antibodies in patients with *Staphylococcus aureus* infection. To our best knowledge, this is the first study to show that EsxA might be a virulence factor and induce the production of anti-EsxA antibodies in patients with *S. aureus* infection. In addition, we further analyzed antimicrobial susceptibility with the EsxA serum antibodies related strains by Phoenix System-100 BD Automated Microbiology, and found that the corresponding positive strains all were multi-drug resistant, of which MRSA to 73.7% (shown in [Table 2](#t2-bjm-44-267){ref-type="table"}).

In summary, we successfully detected the EsxA antibody in the serum of clinical *S. aureus* infectious patients, and found that EsxA were present in multiple drug-resistant strains, especially MRSA strains. Above all, the results indicated that EsxA might as a virulence factor induce antibodies in patients with *Staphylococcus aureus* infection and suggested that EsxA maybe is a very valuable candidate target antigens of the new vaccine for prevention and control of *S. aureus* infection, but it needs further researches to clarify
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###### 

ELISA was detected to anti-EsxA serum antibodies in patients with *S. aureus* infection.

  Sample type   Total cases   Positive cases   Positive rate (%)   M       SD
  ------------- ------------- ---------------- ------------------- ------- -------
  Control       50            0                0                   0.110   0.120
  Test group    78            19               24.35               0.546   0.244

Negative values of the sample co (M+2SD) = 0.350, greater than 0.350 judged as positive.

M: The average OD ~450~ value; SD: Standard deviation.

###### 

Antimicrobial susceptibility analyses *S. aureus* with EsxA antibodies Positive.

  Number   Specimen   Ward              Antimicrobial susceptibility   MRSA                                   
  -------- ---------- ----------------- ------------------------------ ------ --- --- --- --- --- --- --- --- ---
  1        Sputum     Respiratory       R                              R      R   R   R   R   R   R   S   S   Y
  2        Blood      ICU               R                              R      S   R   R   R   R   R   S   S   Y
  3        Sputum     ICU               R                              R      R   R   R   R   R   R   S   S   Y
  4        Urine      Renal             R                              R      R   R   S   R   R   R   S   S   Y
  5        Sputum     Haematology       R                              R      R   R   R   R   R   R   S   S   Y
  6        Abscess    Neurology         R                              R      R   S   R   R   R   R   S   S   Y
  7        Sputum     Cardiac           R                              R      R   R   R   R   R   R   S   S   N
  8        Sputum     Neurosurgery      R                              R      R   R   R   R   R   R   S   S   Y
  9        Abscess    Empyema surgery   R                              R      R   R   R   R   R   R   S   S   N
  10       Abscess    General surgery   R                              R      S   R   R   R   R   R   S   S   Y
  11       Sputum     Cardiac           R                              R      R   R   R   R   R   R   S   S   Y
  12       Sputum     ICU               R                              R      R   R   R   R   R   R   S   S   Y
  13       Sputum     Respiratory       R                              R      R   R   S   R   R   R   S   S   N
  14       Sputum     Empyema surgery   R                              R      S   R   R   R   R   R   S   S   Y
  15       Blood      Cardiac           R                              R      R   R   R   R   R   R   S   S   Y
  16       Sputum     Respiratory       R                              R      R   R   S   R   R   R   S   S   Y
  17       Abscess    Obstetrics        R                              R      R   R   R   R   R   R   S   S   Y
  18       Urine      Renal             R                              R      R   R   R   R   R   R   S   S   N
  19       Sputum     ICU               R                              R      R   R   S   R   R   R   S   S   N

R, resistant; S, susceptible; Y, yes; N, not.

C, Clindamycin; R\*, Rifampicin; T, tetracyline; S, trimethoprim-sulphamethoxazole; A, Amoxicillin/clavulanic acid; E, erythromycin; G, gentamicin; P, penicillin; V, Vancomycin; L, Linezolid.
